Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- PMID: 31492944
- DOI: 10.1038/s41573-019-0038-z
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Abstract
Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.
Similar articles
-
γδT cells, a key subset of T cell for cancer immunotherapy.Front Immunol. 2025 Mar 28;16:1562188. doi: 10.3389/fimmu.2025.1562188. eCollection 2025. Front Immunol. 2025. PMID: 40226616 Free PMC article. Review.
-
Function of γδ T cells in tumor immunology and their application to cancer therapy.Exp Mol Med. 2021 Mar;53(3):318-327. doi: 10.1038/s12276-021-00576-0. Epub 2021 Mar 12. Exp Mol Med. 2021. PMID: 33707742 Free PMC article. Review.
-
Harnessing the power of Vδ2 cells in cancer immunotherapy.Clin Exp Immunol. 2015 Apr;180(1):1-10. doi: 10.1111/cei.12564. Clin Exp Immunol. 2015. PMID: 25469879 Free PMC article. Review.
-
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.Int J Mol Sci. 2021 Aug 18;22(16):8910. doi: 10.3390/ijms22168910. Int J Mol Sci. 2021. PMID: 34445615 Free PMC article. Review.
-
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.Front Immunol. 2024 Mar 21;15:1360237. doi: 10.3389/fimmu.2024.1360237. eCollection 2024. Front Immunol. 2024. PMID: 38576617 Free PMC article. Review.
Cited by
-
Therapeutic avenues for γδ T cells in cancer.J Immunother Cancer. 2023 Nov 24;11(11):e007955. doi: 10.1136/jitc-2023-007955. J Immunother Cancer. 2023. PMID: 38007241 Free PMC article. Review.
-
Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy.Med Oncol. 2023 Nov 11;40(12):352. doi: 10.1007/s12032-023-02226-z. Med Oncol. 2023. PMID: 37950801 Review.
-
γδ T cells as critical anti-tumor immune effectors.Nat Cancer. 2024 Aug;5(8):1145-1157. doi: 10.1038/s43018-024-00798-x. Epub 2024 Jul 26. Nat Cancer. 2024. PMID: 39060435 Review.
-
Decoding γδ T cell anticancer therapies: integrating CRISPR screens with tumor organoids.Signal Transduct Target Ther. 2023 Nov 13;8(1):423. doi: 10.1038/s41392-023-01678-z. Signal Transduct Target Ther. 2023. PMID: 37953309 Free PMC article. No abstract available.
-
Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells.Oncoimmunology. 2022 Feb 1;11(1):2030021. doi: 10.1080/2162402X.2022.2030021. eCollection 2022. Oncoimmunology. 2022. PMID: 35127253 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical